Literature DB >> 7542491

Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation.

V J Canzanello1, S C Textor, S J Taler, D J Wilson, L Schwartz, R H Wiesner, M K Porayko, R A Krom.   

Abstract

Hypertension is common after orthotopic liver transplantation and may be due, in part, to cyclosporin A-induced renal dysfunction and/or enhanced proximal tubular sodium reabsorption. To determine whether enhanced proximal tubular sodium reabsorption is central to the development of posttransplant hypertension, measurements of renal hemodynamics and fractional clearances of lithium and sodium were compared 1 month after orthotopic liver transplantation in previously normotensive patients receiving either cyclosporin A (N = 24) or FK506 (N = 18), an immunosuppressive agent that is structurally unlike cyclosporin A and that has a lower reported incidence of hypertension. Median prednisone doses were 20 and 13 mg/day in the cyclosporin A and FK506 groups, respectively (P < 0.05). At 1 month, mean arterial blood pressure was higher in the cyclosporin A versus the FK506 group: 108 +/- 2 versus 95 +/- 3 mm Hg (P < 0.05). GFR, RBF, and renal vascular resistance were not different between the two groups: 59 +/- 4 and 53 +/- 5 mL/min per 1.73 m2, 439 +/- 28 and 440 +/- 41 mL/min per 1.73 m2, and 22,429 +/- 1,822 and 22,977 +/- 3,506 dyne s/cm5 per 1.73 m2, respectively. Fractional lithium excretion was similar in the cyclosporin A and FK506 groups: 19.9 +/- 2.2 and 19.4 +/- 2.0% (P = not significant) although both values were lower than those of normal controls (25.5 +/- 1.1%) (P < 0.05). Fractional sodium excretion was 2.7 +/- 0.3 and 2.3 +/- 0.4% in the cyclosporin A and FK506 groups, respectively (P = not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542491     DOI: 10.1681/ASN.V5111910

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Potential cardiovascular risk factors in paediatric renal transplant recipients.

Authors:  Jorge R Ferraris; Lidia Ghezzi; Gabriel Waisman; Rafael T Krmar
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

2.  Cyclosporin A stimulates apical Na+/H+ exchange in LLC-PK1/PKE20 proximal tubular cells.

Authors:  Thomas Epting; Kathrin Hartmann; Anna Sandqvist; Roland Nitschke; Nader Gordjani
Journal:  Pediatr Nephrol       Date:  2006-05-11       Impact factor: 3.714

Review 3.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Targeting Calcineurin Inhibitor-Induced Arterial Hypertension in Liver Transplanted Children Using Hydrochlorothiazide.

Authors:  Steffen Hartleif; Hannah Baier; Matthias Kumpf; Rupert Handgretinger; Alfred Königsrainer; Silvio Nadalin; Ekkehard Sturm
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

Review 5.  Pathogenesis of calcineurin inhibitor-induced hypertension.

Authors:  Ewout J Hoorn; Stephen B Walsh; James A McCormick; Robert Zietse; Robert J Unwin; David H Ellison
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

6.  Posttransplant metabolic syndrome.

Authors:  M Shadab Siddiqui; Richard K Sterling
Journal:  Int J Hepatol       Date:  2012-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.